Table 4.
Possible reasons for not achieving superiority
- AFP imbalance favoring sorafenib arm |
- Hepatitis C-related HCC imbalance favoring for sorafenib arm |
- By excluding patients with main portal vein tumor thrombus and tumor burden ≥50%, patients were relatively good prognostic population in both arms, leading to long postprogression survival (PPS) who likely received post trial treatments |
- OS benefit was diluted by long PPS |